DiaMedica Therapeutics (DMAC) Research & Development (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Research & Development of $8.0 million for Q1 2026, up 41.21% year-over-year from $5.7 million in Q1 2025, and up 19.23% quarter-over-quarter from $6.7 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Research & Development (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $8.0 million for Q1 2026.
- In Q1 2026, Research & Development rose 41.21% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $26.9 million (up 28.08% YoY), while the FY2025 annual figure was $24.6 million, up 29.16% from the prior year.
- Research & Development for Q1 2026 stood at $8.0 million, up from $6.7 million in the prior quarter.
- The five-year high for Research & Development was $8.0 million in Q1 2026, with the low at $1.6 million in Q3 2022.
- The 5-year median for Research & Development is $3.7 million (2023), against an average of $4.3 million.
- The sharpest annual moves came in 2022 and 2023: Research & Development decreased 29.67% in 2022, then surged 99.51% in 2023.
- DiaMedica Therapeutics' Research & Development stood at $2.3 million in 2022, then surged by 61.98% to $3.7 million in 2023, then soared by 75.96% to $6.5 million in 2024, then advanced by 3.54% to $6.7 million in 2025, then advanced by 19.23% to $8.0 million in 2026.
- Business Quant data shows DMAC's Research & Development at $8.0 million in Q1 2026, $6.7 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.15 Mn |
| Mar 31, 2026 | 7.99 Mn |
| Dec 31, 2025 | 6.70 Mn |
| Sep 30, 2025 | 6.44 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Dec 31, 2024 | 6.47 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | 3.93 Mn |
| Mar 31, 2024 | 3.68 Mn |
| Dec 31, 2023 | 3.68 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 2.54 Mn |
| Mar 31, 2023 | 3.62 Mn |
| Dec 31, 2022 | 2.27 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 1.96 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 1.87 Mn |
| Sep 30, 2021 | 2.33 Mn |